Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NANT Vaccine Combination in TNBC
NCT03387085Phase 2Terminated
- Sponsor
- ImmunityBio, Inc.
- Start
- Mar 2018
- Primary completion
- Sep 2020
- Modality
- Adenoviral Vectors, Fc-Fusion Proteins, Cancer Vaccines
- Countries
- 1
01
Overview
A Phase 2 trial of nogapendekin alfa inbakicept, haNK, aldoxorubicin, ETBX-011, ETBX-051 in triple-negative breast cancer (TNBC), sponsored by ImmunityBio, Inc.. Started Mar 2018; status: terminated.
02
Drugs
nogapendekin alfa inbakicepthaNKaldoxorubicinETBX-011ETBX-051
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT03387085.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03387085.